PM101: intravenous amiodarone formulation changes can improve medication safety

Bibliography

• Helmy I, Herre JM, Gee G, Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias. J Am Coll Cardiol 1988;12:1015-22
   PubMed Web of Science ®Google Scholar
• Scheinman MM. Parenteral antiarrhythmic drug therapy in ventricular tachycardia/ventricular fibrillation: evolving role of class III agents--focus on amiodarone. J Cardiovasc Electrophysiol 1995;6:914-9
   PubMed Web of Science ®Google Scholar
• Kudenchuk PJ, Cobb LA, Copass MK, Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999;341:871-8
   PubMed Web of Science ®Google Scholar
• Dorian P, Cass D, Schwartz B, Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002;346:884-90
   PubMed Web of Science ®Google Scholar
• American Heart Association. Part 7.3: Management of symptomatic bradycardia and tachycardia. Circulation 2005;112:IV-67-77
   Google Scholar
• Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997;127:294-303
   PubMed Web of Science ®Google Scholar
• Zipes DP, Camm AJ, Borggrefe M, ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e385-484
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS, ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354
   PubMed Web of Science ®Google Scholar
• October TW, Schleien CL, Berg RA, Increasing amiodarone use in cardiopulmonary resuscitation: an analysis of the National Registry of Cardiopulmonary Resuscitation. Crit Care Med 2008;36:126-30
   PubMed Web of Science ®Google Scholar
• Sorrentino A. Update on pediatric resuscitation drugs: high dose, low dose, or no dose at all. Curr Opin Pediatr 2005;17:223-6
   PubMed Web of Science ®Google Scholar
• Kovacikova L, Hakacova N, Dobos D, Amiodarone as a first-line therapy for postoperative junctional ectopic tachycardia. Ann Thorac Surg 2009;88:616-22
   PubMed Web of Science ®Google Scholar
• NHS Centre for the Evaluation of Effectiveness of Health Care. Proposal for the inclusion of amiodarone as an anti-arrhythmic and/or for the treatment of chronic heart failure in the WHO model list of essential medicines. World Health Organization Web site. Available from: http://www.who.int/selection_medicines/committees/expert/17/application/ amiodarone_inclusion.pdf. [Accessed 2 December 2009]
   Google Scholar
• Abraxis Pharmaceutical Products. Amiodarone hydrochloride injection [Prescribing Information]. 2008
   Google Scholar
• Charlier R, Deltour G, Tondeur R, Studies in the benzofuran series. VII. Preliminary pharmacological study of 2-butyl-3-(3,5-diiodo-4- beta-N-diethylaminoethoxybenzoyl)- benzofuran. Arch Int Pharmacodyn Ther 1962;139:255-64
   PubMedGoogle Scholar
• Ravin LJ, Shami EG, Intoccia A, Effect of polysorbate 80 on the solubility and in vivo availability of 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl ketone hydrochloride (SK&F 33134-A). J Pharm Sci 1969;58:1242-5
   PubMed Web of Science ®Google Scholar
• Kessler D, Palepu N, Tustian A, A novel amiodarone microemulsion injectable formulation [abstract]. AAPS PharmSci 2002;4:W4122
   Google Scholar
• Constantinides PP, Tustian A, Kessler DR. Tocol emulsions for drug solubilization and parenteral delivery. Adv Drug Deliv Rev 2004;56:1243-55
   PubMed Web of Science ®Google Scholar
• Kipp JE, Doty MJ, Rebbeck CL, Eilert JY, inventors; Baxter International, assignee. Amiodarone-containing parenteral administration. US6479541; 2002
   Google Scholar
• Elhasi S, Astaneh R, Lavasanifar A. Solubilization of an amphiphilic drug by poly(ethylene oxide)-block-poly(ester) micelles. Eur J Pharm Biopharm 2007;65:406-13
   PubMed Web of Science ®Google Scholar
• Somberg JC, Timar S, Bailin SJ, Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone. Am J Cardiol 2004;93:576-81
   PubMed Web of Science ®Google Scholar
• Somberg JC, Cvetanovic I, Ranade V, Molnar J. Comparative effects of rapid bolus administration of aqueous amiodarone versus 10-minute cordarone i.v. infusion on mean arterial blood pressure in conscious dogs. Cardiovasc Drugs Ther 2004;18:345-51
   PubMed Web of Science ®Google Scholar
• Somberg JC, Cao W, Cvetanovic I, Pharmacology and toxicology of a new aqueous formulation of intravenous amiodarone (amio-aqueous) compared with cordarone i.v. Am J Ther 2005;12:9-16
   PubMedGoogle Scholar
• Somberg JC, Bailin SJ, Haffajee CI, Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol 2002;90:853-9
   PubMed Web of Science ®Google Scholar
• Mosher G, Johnson KT, Gayed AA, inventors; CyDex Inc., assignee. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin. US6869939; 2005
   Google Scholar
• Cushing DJ, Adams MP, Cooper WD, Bioequivalence of 2 intravenous amiodarone formulations in healthy participants. J Clin Pharmacol 2009;49:407-15
   PubMed Web of Science ®Google Scholar
• Cushing DJ, Adams MP, Cooper WD, Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans. Am J Cardiol 2009;104:1152-7
   PubMed Web of Science ®Google Scholar
• Weir SJ, Myers VA, Bengtson KD, Ueda CT. Sorption of amiodarone to polyvinyl chloride infusion bags and administration sets. Am J Hosp Pharm 1985;42:2679-83
   PubMedGoogle Scholar
• Trissel LA. Amiodarone hydrochloride AHFS 24:04.04. In: Trissel LA, editor, Handbook on injectable Drugs. 14th edition. American Society of Health-System Pharmacists. Bethesda, Maryland, USA; 2007. p. 112-18
   Google Scholar
• Ravin LJ, Shami EG, Rattie ES. Micelle formation and its relationship to solubility behavior of 2-butyl-3-benzofuranyl-4- (2-(diethylamino)ethoxy)-3, 5-diiodophenyl ketone hydrochloride. J Pharm Sci 1975;64:1830-3
   PubMed Web of Science ®Google Scholar
• Pearson SD, Trissel LA. Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. Am J Hosp Pharm 1993;50:1405-9
   PubMedGoogle Scholar
• Center for Devices and Radiological Health. Safety assessment of di(2-ethylhexyl)phthalate (DEHP) released from PVC medical devices. Center for Devices and Radiological Health Web site. Available from: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/UCM080457.pdf. [Accessed 6 October 2009]
   Google Scholar
• Kaul AF, Souney PF, Osathanondh R. A review of possible toxicity of di-2-ethylhexylphthalate (DEHP) in plastic intravenous containers: effects on reproduction. Drug Intell Clin Pharm 1982;16:689-92
   PubMedGoogle Scholar
• Capps PA, Robertson AL. Influence of amiodarone injection on the delivery rate of intravenous fluids. Pharm J 1985;234:14-5
   Google Scholar
• Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996;85:1017-25
   PubMed Web of Science ®Google Scholar
• Loftsson T, Jarho P, Masson M, Jarvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2005;2:335-51
   PubMed Web of Science ®Google Scholar
• Stella VJ, He Q. Cyclodextrins. Toxicol Pathol 2008;36:30-42
   PubMed Web of Science ®Google Scholar
• Souney PF, Cowee J, Cushing D, Stability of a cyclodextrin-based IV formulation of amiodarone when diluted with 5 percent dextrose or 0.9 percent sodium chloride injections in both PVC and polyolefin. Annual Summer Meeting of the American Society of Health-System Pharmacists (ASHP); 14 – 17 June 2009; Chicago, IL, USA
   Google Scholar
• Souney PF, Cowee J, Mosher G, Stability of intravenous amiodarone formulations in glass, polyolefin and polyvinylchloride containers over 72 hours. Mid-Year Clinical Meeting of the American Society of Health-System Pharmacists; 7 – 11 December 2008; Orlando, FL, USA
   Google Scholar
• Prism Pharmaceuticals, Inc. Nexterone (amiodarone HCI) [Prescribing Information]. 2008. Available from: http://www.prismpharma.com/assets/Nexterone%20Final%20Approved%20Labeling_1_8_09_ Final%20Edited%20Version.pdf. [Accessed 2 December 2009]
   Google Scholar
• Caruso MC, Idrees U, Lee CK, Assessing the value and developing performance measures of pharmacy services in a pediatric emergency department. Ann Emerg Med 2006;48:S64
   Google Scholar
• Caldwell RD, Tuck BA. Justification and operation of a critical-care satellite pharmacy. Am J Hosp Pharm 1983;40:2141-45
   PubMedGoogle Scholar
• Flynn EA, Pearson RE, Barker KN. Observational study of accuracy in compounding i.v. admixtures at five hospitals. Am J Health Syst Pharm 1997;54:904-12
   PubMed Web of Science ®Google Scholar
• Parshuram CS, To T, Seto W, Systematic evaluation of errors occurring during the preparation of intravenous medication. CMAJ 2008;178:42-8
   PubMed Web of Science ®Google Scholar
• Skibinski KA, White BA, Lin LI, Effects of technological interventions on the safety of a medication-use system. Am J Health Syst Pharm 2007;64:90-6
   PubMed Web of Science ®Google Scholar
• Chow MS. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother 1996;30:637-43
   PubMed Web of Science ®Google Scholar
• Kowey PR, Marinchak RA, Rials SJ, Filart RA. Intravenous amiodarone. J Am Coll Cardiol 1997;29:1190-8
   PubMed Web of Science ®Google Scholar
• Levine JH, Massumi A, Scheinman MM, Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol 1996;27:67-75
   PubMed Web of Science ®Google Scholar
• Scheinman MM, Levine JH, Cannom DS, Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995;92:3264-72
   PubMed Web of Science ®Google Scholar
• Kowey PR, Levine JH, Herre JM, Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995;92:3255-63
   PubMed Web of Science ®Google Scholar
• Cheung AT, Weiss SJ, Savino JS, Acute circulatory actions of intravenous amiodarone loading in cardiac surgical patients. Ann Thorac Surg 2003;76:535-41
   PubMed Web of Science ®Google Scholar
• Vardas PE, Kochiadakis GE, Igoumenidis NE, Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest 2000;117:1538-45
   PubMed Web of Science ®Google Scholar
• Hilleman DE, Spinler SA. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. Pharmacotherapy 2002;22:66-74
   PubMed Web of Science ®Google Scholar
• Krantz JC, Carr CJ, Bird J, Cook S. Sugar alcohols: XXVI. Pharmacodynamic studies of polyoxyalkylene derivatives of hexitol anhdride partial fatty acid esters. J Pharmacol Exp Ther 1948;93:188-95
   PubMed Web of Science ®Google Scholar
• Cushing DJ, Kowey PR, Cooper WD, PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects. Eur J Pharmacol 2009;607:167-72
   PubMed Web of Science ®Google Scholar
• Platou ES, Refsum H. Acute electrophysiologic and blood pressure effects of amiodarone and its solvent in the dog. Acta Pharmacol Toxicol (Copenh) 1986;58:163-8
   PubMedGoogle Scholar
• Sugiyama A, Satoh Y, Hashimoto K. Acute electropharmacological effects of intravenously administered amiodarone assessed in the in vivo canine model. Jpn J Pharmacol 2001;87:74-82
   PubMedGoogle Scholar
• Torres-Arraut E, Singh S, Pickoff AS. Electrophysiologic effects of tween 80 in the myocardium and specialized conduction system of the canine heart. J Electrocardiol 1984;17:145-51
   PubMed Web of Science ®Google Scholar
• Newton PE, Erk SD. Hypotensive effect of tween 80 in dogs [abstract]. Physiol 1981;244
   Google Scholar
• Varma RK, Kaushal R, Junnarkar AY, Polysorbate 80: a pharmacological study. Arzneimittelforschung 1985;35:804-8
   PubMed Web of Science ®Google Scholar
• Masini E, Planchenault J, Pezziardi F, Histamine-releasing properties of polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions 1985;16:470-7
   PubMedGoogle Scholar
• Cushing DJ, Cooper WD, Gralinski MR, Lipicky RJ. The hypotensive effect of intravenous amiodarone is sustained throughout the maintenance period. Clin Exp Pharmacol Physiol 2009 [Epub ahead of print]
   Google Scholar
• Gough WB, Zeiler RH, Barreca P, El-Sherif N. Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs. J Cardiovasc Pharmacol 1982;4:375-80
   PubMed Web of Science ®Google Scholar
• Bicer S, Schwartz DS, Nakayama T, Hamlin RL. Hemodynamic and electrocardiographic effects of graded doses of amiodarone in healthy dogs anesthetized with morphine/alpha chloralose. J Vet Intern Med 2000;14:90-5
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Latini R, Kates RE. Pharmacodynamics of intravenous amiodarone in the dog. J Cardiovasc Pharmacol 1984;6:531-5
   PubMed Web of Science ®Google Scholar
• Singh BN, Jewitt DE, Downey JM, Effects of amiodarone and L8040, novel antianginal and antiarrhythmic drugs, on cardiac and coronary haemodynamics and on cardiac intracellular potentials. Clin Exp Pharmacol Physiol 1976;3:427-42
   PubMed Web of Science ®Google Scholar
• Path GJ, Dai XZ, Schwartz JS, Effects of amiodarone with and without polysorbate 80 on myocardial oxygen consumption and coronary blood flow during treadmill exercise in the dog. J Cardiovasc Pharmacol 1991;18:11-6
   PubMed Web of Science ®Google Scholar
• Talajic M, DeRoode MR, Nattel S. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite. Circulation 1987;75:265-71
   PubMed Web of Science ®Google Scholar
• Petta JM, Zaccheo VJ. Comparative profile of L 3428 and other antianginal agents on cardiac hemodynamics. J Pharmacol Exp Ther 1971;176:328-38
   PubMed Web of Science ®Google Scholar
• Lessa MA, Tibirica E. Acute cardiodepressant effects induced by bolus intravenous administration of amiodarone in rabbits. Fundam Clin Pharmacol 2005;19:165-72
   PubMed Web of Science ®Google Scholar
• Salgado HC, Simoes GM, Santana FV, Negative inotropic and lusitropic effects of intravenous amiodarone in conscious rats. Clin Exp Pharmacol Physiol 2007;34:870-5
   PubMed Web of Science ®Google Scholar
• ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-85
   PubMed Web of Science ®Google Scholar
• Munoz A, Karila P, Gallay P, A randomized hemodynamic comparison of intravenous amiodarone with and without tween 80. Eur Heart J 1988;9:142-8
   PubMed Web of Science ®Google Scholar
• Gallik DM, Singer I, Meissner MD, Hemodynamic and surface electrocardiographic effects of a new aqueous formulation of intravenous amiodarone. Am J Cardiol 2002;90:964-8
   PubMed Web of Science ®Google Scholar
• Ratz Bravo AE, Drewe J, Schlienger RG, Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature. Crit Care Med 2005;33:128-34
   PubMed Web of Science ®Google Scholar
• Toxicological evaluation of certain food additives with a review of general principles and of specifications. Seventeenth report of the joint FAO-WHO Expert Committee on Food Additives. World Health Organ Tech Rep Ser 1974;539:1-40
   PubMedGoogle Scholar
• Evens RP. Toxicity of intravenous benzyl alcohol. Drug Intell Clin Pharm 1975;9:154-5
   Google Scholar
• Smith AL, Haider K, Schachtner JM, Fatal hemolysis after high-dose etoposide: is benzyl alcohol to blame? Pharmacotherapy 2001;21:764-6
   PubMed Web of Science ®Google Scholar
• Lopez-Herce J, Bonet C, Meana A, Albajara L. Benzyl alcohol poisoning following diazepam intravenous infusion. Ann Pharmacother 1995;29:632
   PubMed Web of Science ®Google Scholar
• Gershanik J, Boecler B, Ensley H, The gasping syndrome and benzyl alcohol poisoning. N Engl J Med 1982;307:1384-8
   PubMed Web of Science ®Google Scholar
• Committee on Fetus and Newborn and Committee on Drugs. Benzyl alcohol: toxic agent in neonatal units. Pediatrics 1983;72:356-8
   PubMed Web of Science ®Google Scholar
• Eichbaum FW, Yasaka WJ. Antiarrhythmic effect of solvents: propylene glycol, benzyl alcohol. Basic Res Cardiol 1976;71:355-70
   PubMed Web of Science ®Google Scholar
• Cushing DJ, Cooper WD, Gralinski MR, Comparison of the cardiac electrophysiology and general toxicology of two formulations of intravenous amiodarone in dogs. Cardiovasc Toxicol 2009;9:126-33
   PubMed Web of Science ®Google Scholar
• Cober RE, Schober KE, Hildebrandt N, Adverse effects of intravenous amiodarone in 5 dogs. J Vet Intern Med 2009;23:657-61
   PubMed Web of Science ®Google Scholar
• Somberg JC, Molnar J. The quest for an aqueous amiodarone. Am J Ther 2003;10:458-61
   PubMedGoogle Scholar
• Institute for Safe Medication Practices. ISMP's list of high-alert medications. Institute for Safe Medication Practices Web site. Available from: http://www.ismp.org/Tools/highalertmedications pdf. [Accessed 2 December 2009]
   Google Scholar
• Rich DS. New JCAHO medication management standards for 2004. Am J Health Syst Pharm 2004;61:1349-58
   PubMed Web of Science ®Google Scholar
• Sanborn MD, Moody ML, Harder KA, Second Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems–2008. Am J Health Syst Pharm 2009;66:185-92
   PubMed Web of Science ®Google Scholar
• Fanikos J, Erickson A, Munz KE, Observations on the use of ready-to-use and point-of-care activated parenteral products in automated dispensing cabinets in US hospitals. Am J Health Syst Pharm 2007;64:2037-43
   PubMed Web of Science ®Google Scholar
• American Society of Health-System Pharmacists. Proceedings of a summit on preventing patient harm and death from i.v. medication errors. Am J Health Syst Pharm 2008;65:2367-79
   Google Scholar
• Witte KW, Eck TA, Vogel DP. Decision analysis applied to the purchase of frozen premixed intravenous admixtures. Am J Hosp Pharm 1985;42:835-39
   PubMedGoogle Scholar
• Kirschenbaum BE, Cacace L, Anderson RJ, Personnel time and preparation costs for compounded versus premixed intravenous admixtures in three community hospitals. Am J Hosp Pharm 1988;45:605-8
   PubMedGoogle Scholar
• van der Linden P, Douchamps J, Schmitt C, Ready-to-use injection preparations versus conventional reconstituted admixtures: economic evaluation in a real-life setting. Pharmacoeconomics 2002;20:529-36
   PubMed Web of Science ®Google Scholar
• Sicart M, Besse P, Choussat A, Bricaud H. Hemodynamic effects of intravenous amiodarone in humans. Arch Mal Coeur Vaiss 1977;70:219-27
   PubMedGoogle Scholar
• Anastasiou-Nana MI, Nanas JN, Alexopoulos G, Amiodarone concentration in human myocardium after rapid intravenous administration. Cardiovasc Drugs Ther 1999;13:265-70
   PubMed Web of Science ®Google Scholar
• Kosinski EJ, Albin JB, Young E, Hemodynamic effects of intravenous amiodarone. J Am Coll Cardiol 1984;4:565-70
   PubMed Web of Science ®Google Scholar
• Remme WJ, Kruyssen HA, Look MP, Hemodynamic effects and tolerability of intravenous amiodarone in patients with impaired left ventricular function. Am Heart J 1991;122:96-103
   PubMed Web of Science ®Google Scholar
• Tondeur R, Binon F, inventors; Societe Belge de l'Azate et des Produits Chimiques du Marly, SA., assignee. 3-Diethylaminoethoxybenzoyl- benzofurans. US3248401; 1966
   Google Scholar
• Van Schepdael J, Solvay H. Clinical study of amiodarone in cardiac rhythmic disorders. Presse Med 1970;78:1849-50
   PubMed Web of Science ®Google Scholar
• Benaim R, Uzan C. The antiarrythmic effects of injectable amiodarone (in connection with 153 cases. Rev Med 1978;19:1959-63
   Google Scholar
• Marcus FI, Fontaine GH, Frank R, Grosgogeat Y. Clinical pharmacology and therapeutic applications of the antiarrhythmic agent, amiodarone. Am Heart J 1981;101:480-93
   PubMed Web of Science ®Google Scholar
• Amiodarone. Med Lett Drugs Ther 1986;28:49-50
   PubMed Web of Science ®Google Scholar
• Ehrenpreis S, Somberg JC, inventors; Academic Pharmaceuticals Inc., assignee. Parenteral solutions containing amiodarone in acetate buffer solution. US5234949; 1993
   Google Scholar
• Intravenous amiodarone. Med Lett Drugs Ther 1995;37:114-15
   PubMedGoogle Scholar
• Charlier R, Deltour G, Baudine A, Chaillet F. Pharmacology of amiodarone, an anti-anginal drug with a new biological profile. Arzneimittelforschung 1968;18:1408-17
   PubMed Web of Science ®Google Scholar